Library Catalogue
Excessive pricing in pharmaceutical market : cci should intervene or not?
Parnika Agnihotri
Excessive pricing in pharmaceutical market : cci should intervene or not? - BangaloreBangalore NLSIU 2020 - 39 p. ; 25 cm.
TABLE OF CONTENT INTRODUCTION; WHAT IS EXCESSIVE PRICING? ; A. What is wrong with High prices? ; B. Jurisprudence of Excessive pricing ; SECTION II ; EXCESSIVE PRICING IN PHARMACEUTICAL AT THE LEFT SIDE OF ATLANTIC (EU and UK) ; A. European Union ; A.1 United Brand Company and United Brand Continental BVv. Commission of European Communities ; A.2 Autortiesibu un komunicganas konsultaciju agentura / Latvijas Autoru apvieniba v. Konkurences padome ; A.3 Aspen Pharma: Investigation by DG Competition ; A.4 Denmark- CD Pharma Case ; A.5 Germany- Valium Case ; B. UNITED KINGDOM ; B. 1 Napp Pharmaceuticals Holding v. Director General of Fair Trading ; B. 2 Pfizer/ Flynn v. CMA case ; C. Analysing intervention of EU and UK Competition Authorities in Excessive Pricing; SECTION III ; EXCESSIVE PRICING IN PHARMACEUTICAL AT THE RIGHT SIDE OF ATLANTIC (U.S.) ; A. Conventional Approach Towards Excessive pricing ; B. Brief Overview About Pharmaceutical Market in U.S ; C. Approach OF US after Daraprim Case ; C. 1 Daraprim Case ; C 2 Mylan’s EpiPens Case ; SECTION IV ; REGULATING PHARMACEUTICAL PRICES IN INDIA ; A. Drug Price Control Order, 2013 ; B. Ceiling Price Mechanism ; C. Has India’s Drug Price control mechanism destroyed Competition? ; SECTION V ; CCI SHOULD INTERVENE OR NOT ; A. CCI’s experience against excessive pricing in pharmaceuticals ; A.1 In re: Vivek Sharma v. Becton Dickinson India Pvt. Ltd. &Max Hospital; A.2 Biocon & anr. v. F. Hoffmann- La- Roche Ag & Ors; B. Intervention v. Non- Intervention ; C. PRICES ARE REGULATED: STILL NEED INVETERVENTION OF CCI ; SECTION IV ; CONCLUSION ; REFERENCES ; 1. STATUTES ; 2. CASES ; 3. REPORTS ; 4. BOOKS ; 5. ARTICLES .
Excessive pricing in pharmaceutical market : cci should intervene or not? - BangaloreBangalore NLSIU 2020 - 39 p. ; 25 cm.
TABLE OF CONTENT INTRODUCTION; WHAT IS EXCESSIVE PRICING? ; A. What is wrong with High prices? ; B. Jurisprudence of Excessive pricing ; SECTION II ; EXCESSIVE PRICING IN PHARMACEUTICAL AT THE LEFT SIDE OF ATLANTIC (EU and UK) ; A. European Union ; A.1 United Brand Company and United Brand Continental BVv. Commission of European Communities ; A.2 Autortiesibu un komunicganas konsultaciju agentura / Latvijas Autoru apvieniba v. Konkurences padome ; A.3 Aspen Pharma: Investigation by DG Competition ; A.4 Denmark- CD Pharma Case ; A.5 Germany- Valium Case ; B. UNITED KINGDOM ; B. 1 Napp Pharmaceuticals Holding v. Director General of Fair Trading ; B. 2 Pfizer/ Flynn v. CMA case ; C. Analysing intervention of EU and UK Competition Authorities in Excessive Pricing; SECTION III ; EXCESSIVE PRICING IN PHARMACEUTICAL AT THE RIGHT SIDE OF ATLANTIC (U.S.) ; A. Conventional Approach Towards Excessive pricing ; B. Brief Overview About Pharmaceutical Market in U.S ; C. Approach OF US after Daraprim Case ; C. 1 Daraprim Case ; C 2 Mylan’s EpiPens Case ; SECTION IV ; REGULATING PHARMACEUTICAL PRICES IN INDIA ; A. Drug Price Control Order, 2013 ; B. Ceiling Price Mechanism ; C. Has India’s Drug Price control mechanism destroyed Competition? ; SECTION V ; CCI SHOULD INTERVENE OR NOT ; A. CCI’s experience against excessive pricing in pharmaceuticals ; A.1 In re: Vivek Sharma v. Becton Dickinson India Pvt. Ltd. &Max Hospital; A.2 Biocon & anr. v. F. Hoffmann- La- Roche Ag & Ors; B. Intervention v. Non- Intervention ; C. PRICES ARE REGULATED: STILL NEED INVETERVENTION OF CCI ; SECTION IV ; CONCLUSION ; REFERENCES ; 1. STATUTES ; 2. CASES ; 3. REPORTS ; 4. BOOKS ; 5. ARTICLES .